Dalbavancin: A novel antimicrobial

International Journal of Clinical Practice

Volumn 61, Issue 5, 2007, Pages 853-863

  Chen, A Y ^a   Zervos, M J ^a   Vazquez, J A ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Henry Ford Health System Division of Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 40926; ANTIINFECTIVE AGENT; CEFALEXIN; CEFAZOLIN; CEFTRIAXONE; CEPHALOSPORIN; CLINDAMYCIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; LEVOFLOXACIN; LINEZOLID; METICILLIN; ORITAVANCIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRAM POSITIVE BACTERIUM; HEARING DISORDER; HUMAN; IN VITRO STUDY; INJECTION SITE REACTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LACTOBACILLUS; LEUKOPENIA; LIVER FUNCTION TEST; LOADING DRUG DOSE; LOOSE FECES; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PANCYTOPENIA; PRIORITY JOURNAL; RED MAN SYNDROME; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STREPTOCOCCUS; SYNDROME; THROMBOCYTOPENIA; THRUSH; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VAGINITIS; VESTIBULAR DISORDER; VOMITING;

ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; HUMANS; RESEARCH DESIGN; TEICOPLANIN; TREATMENT OUTCOME;

EID: 34247092376     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01318.x     Document Type: Review

References (48)

1. Ibrahim EH, Sherman G, Ward S et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-55.
2. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005; 52: 113-22.
3. Carmeli Y, Eliopoulos G, Mozaffari E et al. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002; 162: 2223-8.
4. Capitano B, Leshem OA, Nightingale CH et al. Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility. J Am Geriatr Soc 2003; 51: 10-6.
5. Sabath L, Weiner P, Nazeer I. Cryptic vancomycin-resistant staphylococci (CV-RS) as a cause of treatment failure in Staphylococcus aureus bacteremia. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 17-20 September, 1995 (Abstract #LM22).
6. Hiramatsu K, Aritaka N, Hanaki H et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-3.
7. Tenover FC, Lancaster MV, Hill BC et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36: 1020-7.
8. Chang S, Sievert DM, Hageman JC et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348: 1342-7.
9. Tiemersma EW, Bronzwaer SL, Lyytikainen O et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis 2004; 10: 1627-34.
10. Kacica M, McDonald LC. Brief report: vancomycin-resistant Staphylococcus aureus - New York, 2004. MMWR Morb Mortal Wkly Rep 2004; 53: 322-3.
11. Tenover FC, Weigel LM, Appelbaum PC et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 2004; 48: 275-80.
12. Rudrick JT. Michigan Department of Community Health. http://www.michigan.gov/documents/VRSA_Feb05_HAN_118391_7.pdf (accessed February 2007).
13. Ciabatti R, Malabarba A. Semisynthetic glycopeptides: chemistry, structure-activity relationships and prospects. Farmaco 1997; 52: 313-21.
14. Streit JM, Fritsche TR, Sader H et al. Worldwide assessment of dalbavancin activity and spectrum against over 6000 clinical isolates. Diagn Microbiol Infect Dis 2004; 48: 137-43.
15. Malabarba A, Ciabatti R. Glycopeptide derivatives. Curr Med Chem 2001; 8: 1759-73.
16. Buckwalter M, Dowell J. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol 2005; 45: 1279-87.
17. Leighton A, Gottlieb AB, Dorr MB et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 940-5.
18. Dowell JA, Gottlieb AB, Van Saders C et al. The pharmacokinetics and renal excretion of dalbavancin in healthy subjects. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, 26-30 September, 2002 (Abstract #A-1386).
19. Cavaleri M, Riva S, Valagussa A et al. Pharmacokinetics and excretion of dalbavancin in the rat. Antimicrob Chemother 2005; 55 (Suppl. 2): ii31-5.
20. Seltzer E, Dorr MB, Goldstein BP et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003; 37: 1298-303.
21. Dowell JA, Buckwalter M, Seltzer E et al. Dalbavancin penetration into skin supports once-weekly dosing. 15th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark, 2005 (Abstract 895).
22. Andes DR, Craig WA. In vivo pharmacodynamic characterization of dalbavancin (DAL) in the murine thigh infection model. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 2004, 30 October-3 November (Abstract #A-1872).
23. Hackbarth CJ, Lopez S, Trias J et al. In vitro activity of the glycopeptide BI 397 against Staphylococcus aureus and Staphylococcus epidermidis. 39th Inter-science Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 26-29 September, 1999 (Abstract #1283).
24. Gales AC, Sader HS, Jones RN. Antimicrobial activity of dalbavancin tested against gram-positive clinical isolates from Latin American medical centres. Clin Microbiol Infect 2005; 11: 95-100.
25. Lin G, Smith K, Ednie LM et al. Antipneumococcal activity of dalbavancin compared to other agents. Antimicrob Agents Chemother 2005; 49: 5182-4.
26. Dowell JA, Seltzer E, Buckwalter M et al. The pharmacokinetics of dalbavancin in subjects with mild, moderate or severe hepatic impairment. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 30 October-3 November, 2004 (Abstract #A-19).
27. White RJ, Brown GL, Cavelero M et al. Glycopeptide: phase 1 single and multiple-dose placebo controlled intravenous safety, pharmacokinetic, and pharmacodynamic study in healthy subjects. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON, 17-20 September, 2000 (Abstract #682).
28. Streit JM, Fritsche TR, Sader HS et al. Worldwide assessment of dalbavancin activity and spectrum against over 6000 clinical isolates. Diagn Microbiol Infect Dis 2004; 48: 137-43.
29. Candiani G, Abbondi M, Borgonovi M et al. In vitro and in vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother 1999; 44: 179-92.
30. Mushtaq S, Warner M, Johnson A et al. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods. J Antimicrob Chemother 2004; 54: 617-20.
31. Bozdogan B, Esel D, Whitener C et al. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003; 52: 864-8.
32. Lin G, Credito K, Ednie LM et al. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 2005; 49: 770-2.
33. Appelbaum PC, Kelly LM, Ednie LM et al. Comparative activities of dalbavancin (DAL) against staphylococci, including a vancomycin-resistant strain of Staphylococcus aureus. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, 9-12 October, 2003 (Abstract #173).
34. Goldstein EJ, Citron DM, Merriam CV et al. In-vitro activities of dalbavancin and nine comparator agents against anaerobic Grampositive species and corynebacteria. Antimicrob Agents Chemother 2003; 47: 1968-71.
35. Lopez S, Hackbarth C, Romano G et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother 2005; 55 (Suppl. 2): ii21-4.
36. Candiani GP, Romano G, Cavaleri M et al. Efficacy of a single dalbavancin (DA) dose compared with multiple linezolid (LN) doses against penicillin-resistant pneumococci (PRSP) in a lobar pneumonia (LP) model in the immunocompetent rat (IR). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 16-19 December, 2001 (Abstract #B-989).
37. Jabes D, Candiani G, Romano G et al. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob Agents Chemother 2004; 48: 1118-23.
38. Darouiche RO, Mansouri MD. Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo. J Infect 2005; 50: 206-9.
39. Seltzer E, Dorr MB, Goldstein BP et al. Dalbavancin Skin and Soft-Tissue Infection Study Group. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003; 37: 1298-303.
40. Raad I, Darouiche R, Vazquez J et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005; 40: 374-80.
41. Goldstein B, Seltzer E, Flamm R et al. Dalbavancin phase III skin and skin structure (SSSI) studies: pathogens and microbiological efficacy. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 16-19 December, 2005 (Abstract #L-1577).
42. Juregui LE, Babazadeh S, Seltzer E et al. Randomized, double-blind comparison of a once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41: 1407-15.
43. Campbell KC, Kelly E, Targovnik N et al. Audiologic monitoring for potential ototoxicity in a phase I clinical trial of a new glycopeptide antibiotic. J Am Acad Audiol 2003; 14: 157-68.
44. Johnson D, Jones R, Sader H et al. In vitro evaluation of dalbavancin in combination with other classes of antimicrobial. 105th General Meeting of the American Society for Microbiology. Atlanta, GA, 20-24 May, 2005 (Abstract #97089).
45. Streit JM, Sader HS, Fritsche TR et al. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis 2005; 53: 307-10.
46. Jones RN, Sader HS, Fritsche TR. Dalbavancin (DAL; formerly BI397) activity against selected populations of antimicrobial-resistant gram-positive pathogens. 41st Annual Meeting of the Infectious Disease Society of America. San Diego, CA, 9-12 October, 2003 (Abstract #172).
47. Jones RN, Sader HS, Fritsche TR et al. Comparative activity of dalbavancin tested against 7,771 isolates from the USA and Europe (2003). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 30 October-3 November, 2004 (Abstract #E-2009).
48. Beauregard DA, Williams DH, Gwynn MN et al. Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob Agents Chemother 1995; 39: 781-5.